



Memory CD8⁺ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination

Nadia Brasu^{1,2,12}, Ines Elia^{1,3,12}, Valentina Russo^{1,2,12}, Gaia Montacchiesi^{1,2,12},
Simona Aversano Stabile^{1,3,12}, Carlo De Intinis^{1,3}, Francesco Fesi³, Katiuscia Gizzi^{1,3},
Marco Macagno^{1,3}, Monica Montone³, Benedetta Mussolin³, Alba Grifoni^{1,4}, Silvia Faravelli⁵,
Silvia Marchese^{1,6}, Federico Forneris^{1,5}, Raffaele De Francesco^{1,6,7}, Alessandro Sette^{1,4,8},
Vincenzo Barnaba^{1,9,10}, Antonino Sottile³, Anna Sapino^{1,3,11} and Luigia Pace^{1,3,13} ✉

Understanding immune responses to SARS-CoV-2 messenger RNA (mRNA) vaccines is of great interest, principally because of the poor knowledge about the mechanisms of protection. In the present study, we analyzed longitudinally B cell and T cell memory programs against the spike (S) protein derived from ancestral SARS-CoV-2 (Wuhan-1), B.1.351 (beta), B.1.617.2 (delta) and B.1.1.529 (omicron) variants of concern (VOCs) after immunization with an mRNA-based vaccine (Pfizer). According to the magnitude of humoral responses 3 months after the first dose, we identified high and low responders. Opposite to low responders, high responders were characterized by enhanced antibody-neutralizing activity, increased frequency of central memory T cells and durable S-specific CD8⁺ T cell responses. Reduced binding antibodies titers combined with long-term specific memory T cells that had distinct polyreactive properties were found associated with subsequent breakthrough with VOCs in low responders. These results have important implications for the design of new vaccines and new strategies for booster follow-up.

In the last 2 years, infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)¹ has caused remarkable morbidity and mortality. There are hopes that herd immunity, achieved through both natural SARS-CoV-2 infection and vaccination, can control it². Memory B cells, CD4⁺ T cells and CD8⁺ T cells elicited by SARS-CoV-2 mRNA vaccination have a critical role in the protection against infection and represent key determinants in the vaccine boost³. Both Pfizer/BioNTech and Moderna mRNA vaccines show 91% and 93% protective immunity over 7 months^{3–5}, respectively, and up to 95% efficacy in preventing symptomatic COVID-19 disease caused by the wild-type (WT) SARS-CoV-2 and delta and omicron VOCs^{6–8}.

Analyses of SARS-CoV-2-infected individuals has indicated the activation of both B and T cells in some subjects, but also discordant results in others⁹. Although studies in Middle East respiratory syndrome and SARS-CoV-1 infections suggest the long persistence of T cells and their ability to confer protection^{10,11}, the extent to which vaccine-elicited CD4⁺ and CD8⁺ T cell immunity is a correlate of protection against SARS-CoV-2 and VOCs remains poorly understood. The contribution of T cell immunity may in fact be superior compared with antibody protection against divergent VOCs, such as omicron, which escape neutralizing antibodies, as reported in nonhuman primates¹². Based on these considerations,

understanding the mechanisms of protective B and T cell memory responses would allow the development of new vaccination protocols and follow-ups to monitor protection.

In the case of subjects infected with SARS-CoV-2, natural immunity has been reported to be 93–100% protective against symptomatic disease for at least 8 months^{13–15}. As such, individuals resolving previous SARS-CoV-2 infection have been vaccinated within 12 months after infection to achieve long-term protection (hybrid immunity)^{16–18}. Hybrid immunity elicits substantially higher amounts of cross-variant neutralizing antibodies compared with those elicited by the vaccination of naive donors^{16–19}. This strong immunity may be linked to the higher clonal turnover of B cells and greater somatic hypermutation in SARS-CoV-2-recovered compared with naive vaccinated individuals^{20,21}. Although several studies have reported the contribution of virus-specific B and T cells to the protective immunity or immunopathology in SARS-CoV-2-vaccinated, -recovered or -infected individuals^{18,22–24}, it is still unclear whether hybrid immunity generates a more robust repertoire of memory B and T cells when compared with immunity generated after vaccination.

The emergence of the new VOCs such as B.1.351 (beta), B.1.617.2 (delta) and B.1.1.529 (omicron) has brought some insight into the mechanisms of protection of the mRNA vaccines against these

¹G. Armenise-Harvard Immune Regulation Unit, IIGM, Candiolo, TO, Italy. ²Department of Oncology, University of Turin, Turin, Italy. ³Candiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy. ⁴Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA. ⁵Armenise-Harvard Lab. of Structural Biology Dept. Biology and Biotechnology, University of Pavia, Pavia, Italy. ⁶Istituto Nazionale Genetica Molecolare 'Romeo ed Enrica Invernizzi', Milan, Italy. ⁷Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. ⁸Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA, USA. ⁹Pasteur Institute Italy—Fondazione Cenci Bolognietti, Rome, Italy. ¹⁰Departement Scienze Cliniche, Interistiche, Anestesiologiche e Cardiovascolari, Sapienza University, Rome, Italy. ¹¹Department of Medical Sciences, University of Turin, Turin, Italy. ¹²These authors contributed equally: Nadia Brasu, Ines Elia, Valentina Russo. ¹³These authors jointly supervised this work: Anna Sapino, Luigia Pace. ✉e-mail: luigia.pace@iigm.it




Fig. 1 | Longitudinal analysis of humoral responses to BNT162b2 mRNA vaccine. **a**, Experimental design of the study in which 379 individuals were vaccinated with the BNT162b2 mRNA vaccine and PBMCs were isolated before the administration of the first vaccine dose (T0), before the administration of the second vaccine dose at week 3 (3W), week 6 (6W), month 3 (3M) and month 6 (6M) and 1 month after the administration of the third vaccine dose, corresponding to month 10 (10M) after the first vaccine dose, followed by the analysis of humoral and T cell responses against the SARS-CoV-2 spike (S) proteins corresponding to the wild type (S^{WT}), beta (S^B), delta (S^D) and omicron (S^O) variants. **b**, Time series plots of S^{WT} IgG titers measured in SARS-CoV-2-naive, seropositive and SARS-CoV-2-recovered subjects. Abs, antibodies; a.u., arbitrary units; F, female; M, male, NR, nonresponder. Upper LOD = 160 a.u. ml⁻¹. **c**, ELISA of N^{WT} antibody titers in naive ($n = 307$) and recovered ($n = 48$) subjects measured before vaccination (T0). All data are shown as ELISA endpoint titers (ETs) based on a standard. The dotted line indicates the LOD. **d**, Kernel density estimation for S^{WT} IgG titer distribution at 3M after two vaccine doses in vaccinated naive high and low responders (V_{NHR} s and V_{NLR} s; left) and in vaccinated recovered high and low responders (V_{RHR} s and V_{RLR} s; right). The curves are composed of 32,768 points with a distance between adjacent points of 5.82×10^{-3} a.u. ml⁻¹. The total area under the density curve ($A = 1$) is estimated through the Riemann sum with a normalizing constant of 0.999801. **e**, Box plots of S^{WT} IgG titers in V_{NLR} s and V_{NHR} s at T0, 3W, 6W, 3M and 6M. **f**, Pie charts of V_{NLR} s, V_{NHR} s, V_{RLR} s and V_{RHR} s at month 3 postvaccination, with annotations for number and percentage of females and males. Statistics were calculated using two-sided Wilcoxon's rank-sum test (**c** and **e**) or signed-rank test (**b**), with Benjamini-Hochberg correction for multiple testing. * $P \leq 0.05$; ** $P \leq 0.01$; *** $P \leq 0.001$; **** $P \leq 0.0001$. The boxes show median, upper and lower quartiles and the whiskers show 1.5× the interquartile range (IQR) on either side (**b** and **e**) or minimum/maximum (**c**). Each dot represents one subject and the data are pooled.

mutants and the quality and persistence of cross-reactive memory T cells^{2,25–28}. However, although long-term memory B cell and CD4⁺ T cell responses to vaccination against SARS-CoV-2 start to be elucidated^{8,29,30}, the diversification of CD4⁺ and CD8⁺ T cells is not completely understood. This is particularly relevant for delta and omicron, which can evade antibody responses and have been correlated with lower vaccine efficacy against COVID-19 symptoms^{31,32}, although only a minimal number of spike-specific major histocompatibility complex I epitopes are muted compared with WT S (S^{WT})³³.

In the present study, we analyzed the S-specific antibody durability in correlation with memory B cells, CD4⁺ T cells and CD8⁺

T cells in SARS-CoV-2-vaccinated naive (V_N) and SARS-CoV-2-vaccinated COVID-19-recovered (V_R) individuals. Based on B cell responses and distinct polyreactivity of memory CD4⁺ and CD8⁺ T cells, V_N and V_R individuals could be classified as high responders (HRs) and low responders (LRs). Responses in V_N HRs were mainly characterized by increased frequencies of S-specific CCR7⁺CD27⁺CD45RA⁺CD4⁺ central memory 1 T (T_{CM1}) cells and CCR7⁺CD27⁺CD45RA⁺CD8⁺ T_{CM1} cells when compared with V_N LRs. Responses in V_N HRs resembled those of V_R individuals, whereas V_N LRs were characterized by the accumulation of effector memory 2 T (T_{EM2}) cells. These distinct immune responses

correlated with protection against COVID-19 caused by infection with delta and omicron in V_{NHR} s and V_{RL} s.

Results

Distinct S^{WT} antibody titers in V_N and V_R subjects after vaccination. We longitudinally examined a cohort of 379 healthcare workers (69% females, Candiolo Cancer Institute (CCI), a certified COVID-free hospital) who were vaccinated with three doses of the BNT162b2 mRNA vaccine encoding the S^{WT} (ref. 7) at time 0 (T0, first dose), week 3 (second dose) and month 9 after the first dose (third dose) (Fig. 1a and Supplementary Table 1). Based on the results of previous SARS-CoV-2 mRNA PCR tests, COVID-19 diagnosis and antibody titers against the S^{WT} and nucleocapsid (N^{WT}) subjects were classified as: SARS-CoV-2 naive (N), no history of infection, negative mRNA PCR swabs throughout all tests (for testing protocols, see Methods) and negative antibody responses to S^{WT} and N^{WT} ($n=307$, 67% females); seropositive, no history of infection based on negative mRNA PCR tests, but low titers of antibodies specific to S^{WT} and/or N^{WT} ($n=24$, 79% females); and recovered (R), with a past infection event documented by positive SARS-CoV-2 mRNA PCR swabs and mild COVID-19 symptoms ($n=48$, 70% females) (Fig. 1b,c and Extended Data Fig. 1a,b). Peripheral blood was collected a few hours before the administration of the first vaccine dose (T0), and week 3, week 6, month 3, month 6 and month 10 postvaccination.

Based on the S^{WT} -specific immunoglobulin (Ig)M and IgG titers in plasma during the first 6 months postvaccination, 10 (of the 379, 67% females) participants did not respond to the vaccine (Fig. 1b and Extended Data Fig. 1b). At each time point, the median of S^{WT} -specific IgM titers was not significantly different between V_N and V_R subjects (Extended Data Fig. 1b). In contrast, V_R subjects had higher baseline and a delayed decrease in S^{WT} -specific IgG concentration compared with V_N subjects at all timepoints (Fig. 1b). In particular, S^{WT} -specific IgG amounts significantly increased compared with T0 at weeks 3 and 6 postvaccination and gradually decreased at months 3 and 6 in V_N subjects, whereas they remained high at month 3 and decreased at month 6 in V_R subjects, although less dramatically than in V_N subjects (Fig. 1b). After a peak between weeks 1 and 3, the S^{WT} -specific IgG titers declined between months 3 and 6 in V_N subjects (Fig. 1b). At month 3 postvaccination, the Kernel density estimation of S^{WT} -specific IgG titers showed a bimodal distribution in V_N subjects (Fig. 1d). Based on the antimode value (that is, the least frequent value between the modes, cut-off 135 a.u. ml^{-1}), the 298 V_N subjects were divided into V_{NLR} s ($n=236$, 64% females) and V_{NHR} s ($n=62$, 81% females) (Fig. 1e). Similarly, based on the antimode value (112 a.u. ml^{-1}), the V_R cohort was classified as V_{RHR} s ($n=39$, 72% females) and V_{RL} s ($n=9$, 56% females) (Fig. 1d and Extended Data Fig. 1c). Both V_{NHR} s and V_{NLR} s were negative for N^{WT} -specific IgGs (Fig. 1c). Of note, at month 3 postvaccination, there was increased frequency of females among V_{NHR} s (81%) compared with V_{RL} s (64%, Fisher's test $P=0.01481$; Fig. 1f). No correlation was found between age and S^{WT} -specific IgG titers at month 6 postvaccination (Extended Data Fig. 1d), although S^{WT} -specific IgG titers were significantly higher in the 20- to 29-year-old group than in all the others (Extended Data Fig. 1e). These results indicated durable S^{WT} -specific IgG responses in all cohorts, with higher titers in V_R than V_N subjects, and distinguished V_{NHR} s and V_{NLR} s based on the bimodal distribution of S^{WT} -specific IgG titers.

mRNA vaccine induces B cell responses and RBD antibodies.

To determine whether the S^{WT} -specific IgG titers correlated with B cell frequencies, peripheral blood mononuclear cells (PBMCs) collected at T0, week 6 and month 6 postvaccination were stained with SARS-CoV-2 S^{WT} tetramers in the presence of antibodies for CD19, CD27, IgG, IgA and IgM (Fig. 2a and Extended Data Fig. 2a). No

difference emerged in terms of the percentage of CD19⁺ B cells at all timepoints tested (Extended Data Fig. 2b). Lower percentages of S^{WT} -specific B cells were found in V_{NLR} s and V_{NHR} s compared with V_R subjects at T0 and week 6 postvaccination (Fig. 2b and Extended Data Fig. 2a,c), but the frequency of S^{WT} -specific B cells increased significantly in V_{NHR} s compared with V_{NLR} s at month 6 postvaccination (Fig. 2b). The S^{WT} -specific IgG titers correlated with the frequency of S^{WT} -specific tetramer⁺ B cells at month 6 in V_{NHR} s and V_R subjects (Fig. 2c). The frequency of S^{WT} -specific tetramer⁺ B cells and CD27⁺ IgG⁺ B cells were higher in V_R subjects than in both V_{NLR} s and V_{NHR} s, especially at week 6 postvaccination (Fig. 2b,d). However, at month 6, the frequencies of S^{WT} -specific B cells and CD27⁺ IgG⁺ B cells equalized in V_R subjects and V_{NHR} s, whereas the frequency of S^{WT} -specific B cells and the numbers of CD27⁺ IgG⁺ B cells remained significantly lower in V_{NLR} s than in the other two cohorts (Fig. 2b,d). The frequencies of S^{WT} -specific CD27⁺ IgM⁺ B cells decreased in V_{NHR} s and V_{NLR} s (Extended Data Fig. 2d), whereas the frequency and numbers of S^{WT} -specific CD27⁺ IgA⁺ B cells increased (Fig. 2e and Extended Data Fig. 2e) at month 6 postvaccination.

Next we measured the antibody titers against S^{WT} receptor-binding domain (RBD^{WT}) in the plasma collected from 30 V_{NHR} s, 30 V_{NLR} s and 26 V_R subjects at T0, month 3 and month 6 (Fig. 3a and Extended Data Fig. 3a). Although RBD^{WT}-specific antibodies were not detected in V_{NHR} s and V_{NLR} s at T0, robust RBD^{WT}-specific antibody titers were detected in V_{NHR} s and V_R subjects compared with V_{NLR} s at month 6 postvaccination (Fig. 3a). A similar range of percentage values was detected for delta RBD (RBD^D) IgGs, whereas omicron RBD (RBD^O) crossbinding IgG titers were reduced in both V_{NHR} s and V_R subjects at months 3 and 6 (Fig. 3a). The RBD^D and RBD^O antibody titers were always lower in V_{NLR} s than in the other 2 cohorts at months 3 and 6 postvaccination (Fig. 3a).

To quantify the corresponding neutralizing capacity of S RBD-specific antibodies, we generated pseudotype viruses encoding S-RBD^{WT}, -RBD^D and -RBD^O. At month 6, V_{NLR} s had reduced ancestral pseudovirus-neutralizing responses compared with V_{NHR} s, with minimal activity against delta and complete absence of neutralization against omicron particles (Fig. 3b), and the reduced neutralization against the ancestral pseudoviruses in V_{NLR} s correlated with the reduced RBD^{WT} antibody titers (Fig. 3c). Overall, these results indicated poor crossbinding of RBD-specific antibodies in V_{NLR} s against delta and omicron variants, with almost complete lack of neutralizing activity 6 months postvaccination.

T cell polyreactivity varies among V_{NLR} s, V_{NHR} s and V_R subjects.

To determine the polyreactivity of memory T cell responses against S^{WT} , S^D , S^O and beta S (S^B), PBMCs were stimulated for 24 h with peptide megapools spanning the aforementioned proteins, whereas PBMC cultures in medium or with interleukin (IL)-2 and CD3 plus CD28 antibodies were used as negative (background) or positive controls, respectively. To measure the CD4⁺ and CD8⁺ T cell responses elicited by vaccination, we quantified the frequency of CD25⁺CD69⁺ T cells in the PBMCs from 25 V_{NLR} s, 24 V_{NHR} s and 12 V_R subjects 24 h poststimulation and after background subtraction (as the percentage of CD25⁺CD69⁺ T cells measured in the paired PBMCs cultured in medium) at T0 and month 6 postvaccination (Fig. 4a and Extended Data Fig. 4a–c). No difference was observed in terms of percentages of total CD4⁺ and CD8⁺ T cells before stimulation (Extended Data Fig. 4d,e) and background activation (Extended Data Fig. 4f,g) in all three cohorts. The percentages of polyspecific CD4⁺ T cells to both S^{WT} and S^B peptide megapools were significantly higher in V_R subjects than in V_{NHR} s and V_{NLR} s at T0 (Fig. 4b and Extended Data Fig. 4f). The percentage of CD25⁺CD69⁺CD4⁺ T cells significantly increased on stimulation with S-peptide megapools in both V_{NHR} s and V_{NLR} s at month 6 compared with T0 (Fig. 4b and Extended Data Fig. 5a). Similar




Fig. 2 | Dynamics of memory B cell responses after BNT162b2 mRNA vaccination. **a**, Representative flow cytometry dot plots of S^{WT} -tetramer $^{+}$ cells on gated CD19 $^{+}$ B cells and of CD27 $^{+}$ IgG $^{+}$ cells on gated S^{WT} -tetramer $^{+}$ B cells from V_{NLR} , V_{NHR} and V_R subjects at month 6. **b**, Flow cytometry analysis showing the percentage of S^{WT} -tetramer $^{+}$ B cells in V_{NLR} , V_{NHR} and V_R subjects at T0, week 6 and month 6. **c**, Spearman's correlation plot between S^{WT} IgG titers and percentage of S^{WT} -tetramer $^{+}$ B cells in V_{NLR} , V_{NHR} and V_R subjects at month 6 measured by flow cytometry; V_{NLR} s: $R=0.388$ and $P=NS$ (not significant); V_{NHR} s: $R=0.4471$ and $P<0.05$; V_R subjects: $R=0.4384$ and $P<0.05$. **d,e**, Flow cytometry analysis showing the percentage and number per 10^6 PBMCs of CD27 $^{+}$ IgG $^{+}$ S^{WT} $^{+}$ B cells (**d**) and the percentage of CD27 $^{+}$ IgG $^{+}$ S^{WT} $^{+}$ B cells (**e**) in V_{NLR} , V_{NHR} and V_R subjects at T0, week 6 and month 6. Below: percentages of subjects with active responses >0.01 . The dashed black line shows the LOD. The same subjects were analyzed longitudinally at T0: V_{NLR} s ($n=25$), V_{NHR} s ($n=24$), V_R subjects ($n=12$); 6 W: V_{NLR} s ($n=12$), V_{NHR} s ($n=17$), V_R subjects ($n=10$); and 6 M: V_{NLR} s ($n=26$), V_{NHR} s ($n=29$), V_R subjects ($n=22$). The box plots indicate median, IQR and minimum/maximum. Each dot of the box plots represents the average across three technical replicates of the same subject; the data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon's rank-sum test. * $P<0.05$; ** $P<0.01$; *** $P<0.001$; **** $P<0.0001$.




Fig. 3 | Anti-RBD-binding antibodies and neutralizing activity against ancestral and VOCs-derived spike. **a**, ELISA showing SARS-CoV-2 S-RBD^{WT}, -RBD^D and -RBD^O IgG titers in V_NLRs, V_NHRs and V_R subjects in plasma at T0, 3M and 6M. ELISA results shown as ETs based on a standard. The dotted lines represent the LOD. At T0: V_NLRs (*n*=30), V_NHRs (*n*=30), V_R subjects (*n*=26); 3M: V_NLRs (*n*=28), V_NHRs (*n*=27), V_R subjects (*n*=25); 6M: V_NLRs (*n*=30), V_NHRs (*n*=29), V_R subjects (*n*=26). **b**, Neutralization assay showing 50% neutralizing dose titers (ND₅₀) against S-RBD^{WT}, -RBD^D and -RBD^O measured by pseudovirus (PSV)-neutralizing assay in plasma from V_NLRs (*n*=20) and V_NHRs (*n*=20) at month 6. **c**, Spearman's correlation plots showing PSV ND₅₀ and IgG ELISA ETs against S-RBD^{WT}, -RBD^D and -RBD^O in plasma from V_NLRs (*n*=20) and V_NHRs (*n*=20) at month 6. V_NLRs, RBD^{WT}: *R*=0.721 and *P*<0.001, RBD^D: *R*=0.2305 and *P*=NS, RBD^O: *P*=NS; V_NHRs, RBD^{WT}: *R*=0.2168 and *P*=NS, RBD^D: *R*=0.6282 and *P*<0.01, RBD^O: *R*=0.4277 and *P*<0.01. NA indicates no neutralizing activity. The same subjects were longitudinally analyzed. The box plots indicate median, IQR and minimum/maximum. Each dot of box plots represents the average across two (**a**) and three (**b**) technical replicates of the same subject; the data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon's signed-rank and two-sided Wilcoxon's rank-sum test. ***P*<0.01; ****P*<0.001; *****P*<0.0001.

observations were made for CD25⁺CD69⁺CD8⁺ T cell responses to the S^{WT}, S^D and S^O (Fig. 4c and Extended Data Figs. 4g and 5b). No differences were observed in terms of activation with the positive controls in all examined conditions (Extended Data Fig. 5c,d). Stimulation with S^{WT}, S^D and S^O peptide megapools elicited a consistent increase in the percentage of CD25⁺CD69⁺CD8⁺ T cells in both V_NHRs and V_NLRs at month 6 postvaccination (Fig. 4c and Extended Data Fig. 5b).


We next assessed the effector T cell activity by investigating the expression of granzyme B and the effector cytokines interferon (IFN)- γ , tumor necrosis factor (TNF)- α and IL-2 after 14h of stimulation of PBMCs isolated at T0 and month 6 with S-peptide megapools derived from WT, delta, omicron and beta variants, using PBMCs cultured with IL-2 and CD3 plus CD28 antibodies or medium as positive or negative controls, respectively (Extended Data Fig. 6a). There were no differences in the percentage of


granzyme B⁺ cells between T0 and month 6 in both V_NLR and V_NHR subjects (data not shown), whereas IFN- γ expression was elicited by all S-derived megapools in antigen-specific CD4⁺ T cells and CD8⁺ T cells, although at different levels, at month 6 (Fig. 4d). A significant increase in the T cell responses to S^O peptides was observed in V_NHRs and V_R subjects compared with V_NLRs (Fig. 4d), indicating a higher frequency of polyreactive T cells in those samples. By contrast, the percentages of IL-2⁺ (Extended Data Fig. 6b) and TNF- α +CD4⁺ or -CD8⁺ T cells (Extended Data Fig. 6c) were quite similar across all cohorts, as well as in the PBMCs stimulated with IL-2 and CD3 plus CD28 antibodies (positive controls; Extended Data Fig. 6d). These results showed that polyreactive, S-specific memory CD4⁺ and CD8⁺ T cell responses could be detected until month 6 postvaccination and that the frequencies of IFN- γ +CD4⁺ T cells or IFN- γ +CD8⁺ T cells reactive against S^O were reduced in V_NLRs compared with V_NHRs and V_R individuals.

Fig. 4 | Analysis of specific CD4⁺ and CD8⁺ T cell responses against S^{WT}, S^D, S^O and S^B in V_NLRs, V_NHRs and V_R subjects. **a**, Representative flow cytometry dot plots of CD25 versus (vs) CD69 cells on gated CD4⁺ (left) and CD8⁺ (right) T cells from V_NLRs, V_NHRs and V_R subjects at month 6, after 24h incubation with medium (Unstimulated) or S^{WT} peptide megapools. **b,c**, Flow cytometry analysis showing the percentage of CD25⁺CD69⁺ cells in CD4⁺ T cells (**b**) and CD8⁺ T cells (**c**) from V_NLRs, V_NHRs and V_R subjects at T0 and 6M, 24h after incubation with S^{WT}, S^D, S^O or S^B. Below: percentages of subjects with active responses >0.01. **d**, Flow cytometry analysis showing the percentage of IFN- γ ⁺ cells in CD4⁺ T cells and CD8⁺ T cells from V_NLRs, V_NHRs and V_R subjects at month 6, after 14h incubation with S^{WT}, S^D, S^O or S^B. Below: percentages of subjects with active responses >0.01. Data are represented with background subtraction from paired unstimulated controls. The same subjects were analyzed longitudinally at T0 and 6M: V_NLRs (*n*=25), V_NHRs (*n*=24) and V_R subjects (*n*=12). The box plots indicate median, IQR and minimum/maximum. Each dot of the box plots represents the average across three technical replicates of the same subject; the data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon's signed-rank and two-sided Wilcoxon's rank-sum test. **P*<0.05; ***P*<0.01; ****P*<0.001; *****P*<0.0001.

Distinct memory T cell subsets react against S^{WT} and S^o . Several subsets of $CD4^+$ and $CD8^+$ T cells, such as $CCR7^+CD45RA^-$ T_{CM} cells, $CCR7^-CD27^+CD45RA^-$ T_{EM1} cells, $CCR7^-CD27^-CD45RA^-$

T_{EM2} cells and terminally differentiated effector memory $CD45RA^+$ T cells (T_{EMRA} cells) have been described^{34–37}. Based on immune phenotype, transcriptional and epigenetic programs, $CD8^+$ T_{EM1} cells





are closely related to $CD8^+ T_{CM}$ cells, and have been suggested to exert memory functions in peripheral tissues³⁴, whereas $CD8^+ T_{EM2}$ cells resemble differentiated $CD8^+ T_{EMRA}$ cells^{34,37}. The role of these T cell subsets in protection against infections is still unclear. To

evaluate the heterogeneity of memory $CD4^+$ and $CD8^+$ T cells, PBMCs collected at T0 and month 6 from 25 V_{NLR} s, 24 V_{NHR} s and 12 V_R subjects were stimulated for 24 h with peptides covering S^{WT} , S^D , S^B and S^O , or with positive (IL-2 and CD3 plus CD28 antibodies)

Fig. 5 | BNT162b2 mRNA vaccine promotes distinct memory CD4⁺ T cell profiles in V_NLR, V_NHR and V_R cohorts. **a**, Representative flow cytometry dot plots of CCR7 and CD27 on gated CD25⁺CD69⁺CD45RA⁺CD4⁺ T cells in V_NLRs, V_NHRs and V_R subjects at month 6, after 24h incubation with medium (unstimulated) or S^{WT}. **b–d**, Flow cytometry analysis showing the percentage of CCR7⁺CD27⁺CD45RA⁺ T_{CM1} (**b**), CCR7⁺CD27⁺CD45RA⁺ T_{EM1} (**c**) and CCR7⁺CD27⁺CD45RA⁺ T_{EM2} (**d**) cells on gated CD25⁺CD69⁺CD4⁺ T cells collected at T0 and 6M, after 24h incubation with S^{WT}, S^D, S^O or S^B. Below: percentages of subjects with T_{CM1} (**b**), T_{EM1} (**c**) and T_{EM2} (**d**) CD25⁺CD69⁺CD45RA⁺CD4⁺ T cell active responses >LOS. Data are represented with background subtraction from paired unstimulated controls. The dotted black lines represent the LOD and the dotted green lines the LOS. The same subjects were longitudinally analyzed: V_NLRs (n = 25), V_NHRs (n = 24) and V_R subjects (n = 12). The box plots indicate median, IQR and minimum/maximum. Each dot of box plots represents the average across three technical replicates of the same subject; the data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon's signed-rank and two-sided Wilcoxon's rank-sum test. *P < 0.05; **P < 0.01.

and negative (medium) controls. The expression of several differentiation markers was assessed on gated S-specific CD25⁺CD69⁺CD4⁺ T cells and CD25⁺CD69⁺CD8⁺ T cells by flow cytometry to distinguish naive CD45RA⁺CCR7⁺CD27⁺ T cells (T_N cells), CCR7⁺CD27⁺CD45RA⁺ T_{CM1} cells, CCR7⁺CD27⁺CD45RA⁺ T_{CM2} cells, CCR7⁺CD27⁺CD45RA⁺ T_{EM1} cells, CCR7⁺CD27⁺CD45RA⁺ T_{EM2} cells and CCR7⁺CD45RA⁺T_{EMRA} cells (Fig. 5a, Extended Data Figs. 4b,c, 7a–f and 8a–f). V_R subjects had the highest frequencies of CD4⁺ T_{CM1} cells and CD4⁺ T_{EM1} cells in response to all S megapools at T0 (Fig. 5a–c and Extended Data Fig. 7a,b). Some V_N subjects (<20% of responders in all conditions) showed cross-reactive responses to S peptides of CD4⁺ T_{CM1} cells at T0 (Fig. 5b), probably as a result of T cell responses elicited after SARS-CoV-2 exposure without infection or infections with α- and β-coronaviruses^{29,38–40}. The percentages of CD25⁺CD69⁺CD4⁺ T_{CM1} cells specific for S^D, S^O and S^B were significantly higher in V_NLRs at month 6 compared with T0, as well as in V_NHRs activated with all S-peptide megapools, except for S^B (Extended Data Fig. 7a). However, the frequency of S^{WT}- and S^D-specific CD4⁺ T_{CM1} cells was significantly reduced in V_NLRs compared with the frequency of S-specific CD4⁺ T_{CM1} cells in V_NHRs and V_R subjects (Fig. 5b). The frequencies of S^{WT}-specific CD4⁺ T_{EM1} cells were increased in all cohorts at month 6 compared with T0 (Extended Data Fig. 7b), but increased frequencies of polyreactive CD4⁺ T_{EM1} cells were measured only in V_NHRs (Extended Data Fig. 7b) at month 6 postvaccination. Stronger cross-reactive CD4⁺ T_{EM1} cells were also measured in V_R subjects compared with V_NHRs and V_NLRs at month 6 postvaccination (Fig. 5c). Last, the percentage of S^{WT}- and S^D-specific CD4⁺ T_{EM2} cells was significantly increased in V_NLRs after vaccination (Extended Data Fig. 7c), and they significantly increased in V_NHRs and V_NLRs compared with V_R subjects (Fig. 5d). No differences were observed when the PBMCs were stimulated with a positive control (Extended Data Fig. 8a,c,e). Higher frequencies of S-specific CD4⁺ T_N cells were measured in V_NHRs compared with V_NLRs before vaccination (T0; Extended Data Fig. 9a), suggesting a wider T cell receptor (TCR) repertoire in the T_N cell subset in V_NHRs. We did not detect differences in the percentage of CD4⁺ T_{CM2} and CD4⁺ T_{EMRA} subsets in all cohorts and timepoints (Extended Data Fig. 9b,c).

Vaccination promoted a significant increase in the magnitude of percentages of S-specific CD8⁺ T_{CM1} cells in V_NHRs (Extended Data Fig. 7d), but only S^{WT}- and S^B-specific CD8⁺ T_{CM1} cells in V_NLRs (Extended Data Fig. 7d) at month 6 postvaccination compared

with T0. V_R subjects also had S-specific CD8⁺ T_{CM1} cell responses at month 6 (Fig. 6a,b and Extended Data Fig. 7d). Of note, there was a significant reduction in the response of V_NLR CD8⁺ T_{CM1} cells to S^{WT}, S^O and S^D peptide megapools compared with V_NHRs (Fig. 6b). We did not observe major differences in the reactivity of CD8⁺ T_{EM1} cells of V_NHRs compared with V_NLRs before and after vaccination (Fig. 6a,c and Extended Data Fig. 7e), whereas a significant enrichment of S-polyreactive CD8⁺ T_{EM2} cells was measured in V_NLRs at month 6 postvaccination compared with T0 (Extended Data Fig. 7f). Similar frequencies of CD8⁺ T_N cells were found at T0 and month 6 (Extended Data Fig. 9d), whereas CD8⁺ T_{CM2}- and CD8⁺ T_{EMRA}-specific responses, in terms of percentages, were barely detectable at both timepoints (Extended Data Fig. 9e,f). These observations indicated that, at month 6 postvaccination, higher frequencies of polyreactive CD4⁺ T_{CM1} cells (Fig. 5b) and CD8⁺ T_{CM1} cells (Fig. 6b) were present in V_NHRs compared with V_NLRs, whereas V_NLR memory responses were characterized by the accumulation of CD4⁺ (Fig. 5d and Extended Data Fig. 7c) and CD8⁺ (Fig. 6d and Extended Data Fig. 7f) T_{EM2} cells.


RBD antibodies and T cells correlate with COVID-19 protection.

To investigate how VOC-specific immune responses are modulated after the third vaccine dose and how they correlate with protection, we examined the VOC-RBD-binding antibodies and the T cell responses against S^{WT}, S^D, S^O and S^B at 1 month post-BNT162b2 mRNA vaccine booster, which was administered to all participants at month 9 after the first dose. The RBD^{WT}- and RBD^D-binding antibody titers were reduced in V_NLRs compared with V_NHRs and V_R subjects even at month 10 (corresponding to 1 month after the third booster) (Fig. 7a, upper panel). However, the postbooster at month 10 RBD-specific antibody titers were significantly increased in all cohorts, 10-fold for RBD^{WT} and RBD^D and 100-fold for RBD^O compared with month 6 (Fig. 7a, lower panel). The fold-change for RBD^O was significantly lower in V_NLRs and V_R subjects than in V_NHRs (Fig. 7a, upper panel). At month 1 postbooster, activated CD25⁺CD69⁺CD4⁺ T cells were detected in both V_NHRs and V_NLRs after stimulation with S (Fig. 7b); however, there was no significant increase in the frequencies of S-specific CD25⁺CD69⁺CD4⁺ T cells postboost compared with month 6 postvaccination, except for the S^{WT}-specific CD25⁺CD69⁺CD4⁺ T cells in V_NHRs (Fig. 7c and Extended Data Fig. 10a). The frequencies of CD25⁺CD69⁺CD8⁺

Fig. 6 | BNT162b2 mRNA vaccine promotes distinct memory CD8⁺ T cell profiles in V_NLR, V_NHR and V_R cohorts. **a**, Representative flow cytometry dot plots of CCR7 and CD27 on gated CD25⁺CD45RA⁺CD69⁺CD8⁺ T cells in V_NLRs, V_NHRs and V_R subjects at month 6, measured by flow cytometry, after 24h incubation with medium (unstimulated) or S^{WT}. **b–d**, Flow cytometry analysis showing the percentage of CCR7⁺CD27⁺CD45RA⁺ T_{CM1} (**b**), CCR7⁺CD27⁺CD45RA⁺ T_{EM1} (**c**) and CCR7⁺CD27⁺CD45RA⁺ T_{EM2} (**d**) cells among CD25⁺CD69⁺CD8⁺ T cells collected at T0 and 6M, after 24h incubation with S^{WT} or S^D, S^O and S^B. Below: percentage of subjects with T_{CM1} (**b**), T_{EM1} (**c**) and T_{EM2} (**d**) CD25⁺CD69⁺CD45RA⁺CD8⁺ T cell active responses >LOS. Data are represented with background subtraction from paired unstimulated controls. The dotted black lines represent the LOD and the dotted green lines the LOS. The same subjects were longitudinally analyzed: V_NLRs (n = 25), V_NHRs (n = 24) and V_R subjects (n = 12). The box plots indicate median, IQR and minimum/maximum. Each dot of box plots represents the average across three technical replicates of the same subject; the data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon's signed-rank test and two-sided Wilcoxon's rank-sum test. *P < 0.05; **P < 0.01; ****P < 0.0001.

T cells in V_N LRs were low at month 1 postboost (Fig. 7d and Extended Data Fig. 10b), without any significant increase compared with month 6 postvaccination (Fig. 7e).

Last, to test whether the different humoral responses and T_M cells' fate diversification correlated with protection, we assessed how many vaccinated individuals had breakthrough infections with






Fig. 7 | Analysis of circulating antibodies and specific CD4⁺ T cell and CD8⁺ T cell responses in V_NLRs, V_NHRs and V_R subjects after the third dose of the BNT162b2 mRNA vaccine. **a**, ELISA showing S-RBD^{WT}, -RBD^D and -RBD^G binding IgG titers in V_NLRs, V_NHRs and V_R subjects at month 10 (upper panel) and the corresponding ratio vs pre-boost values at month 6 (lower panel). ELISA results shown as ETs based on a standard. The dotted lines represent the LOD. At month 10: V_NLRs (*n* = 24), V_NHRs (*n* = 20) and V_R subjects (*n* = 17). At month 10 vs 6: V_NLRs (*n* = 23), V_NHRs (*n* = 19) and V_R subjects (*n* = 13). **b–e**, Flow cytometry analysis showing the percentage of CD25⁺CD69⁺ cells on gated CD4⁺ (**b**) and CD8⁺ (**d**) T cells from V_NLRs (*n* = 13) and V_NHRs (*n* = 13) at month 10, after 24h incubation with S^{WT}, S^D, S^O or S^B, and the corresponding ratio vs pre-boost values at month 6 (**c** and **e**). ND, not detected. Below: percentages of subjects with active responses >0.01. Data are represented with background subtraction from paired unstimulated controls. The same subjects were longitudinally analyzed. The box plots indicate the median, IQR and minimum/maximum. Each dot of the box plots represents the average across two (**a**) and three (**b–e**) technical replicates of the same subject. Statistics were calculated using two-sided Wilcoxon's signed-rank test and two-sided Wilcoxon's rank-sum test. The significance of the ratio was assessed by Wilcoxon's signed-rank *t*-test compared with a hypothetical median of 1. **P* < 0.05; ***P* < 0.01; ****P* < 0.001; *****P* < 0.0001.




Fig. 8 | Delta and omicron breakthrough infection in V_NLRs, V_NHRs and V_R subjects. **a**, Prevalence of the indicated variants from January 2021 to 15 April 2022 in Italy. **b**, Percentage of COVID-19 cases correlated with the indicated SARS-CoV-2 variant breakthrough in V_NLRs, V_NHRs, V_RLRs and V_RHRs after two (left) and three (right) vaccine doses. Fisher's exact test was calculated in J (*P* = 0.01 V_NLRs versus V_NHRs; *P* = 0.0006 V_RLRs versus V_RHRs).

symptoms after immunization with two or three vaccine doses. The SARS-CoV-2 pandemic in Italy has been characterized by four distinct infection waves (www.ecdc.europa.eu), with delta accounting for >90% of the virus sequences in December 2021, and omicron for >90% since the beginning of 2022 (Fig. 8a). Of the study subjects, 1.5% (5/346) were infected with SARS-CoV-2 and developed mild COVID-19 (assessed by positive SARS-CoV-2 PCR swabs, cough and a few days of fever) within 8 months postvaccination, corresponding to the delta wave (Fig. 8b), and 7.33% (25/341) were infected with SARS-CoV-2 between 10 and 15 months postvaccination, corresponding to omicron (Fig. 8a). All subjects who developed COVID-19 symptoms after the second vaccine dose were V_N LRs (5 subjects, 2.12%), (Fig. 8b). Among the V_N LR subjects, 9.1% (21/231) developed symptomatic disease after three vaccine doses, corresponding to the omicron wave (Fig. 8b), suggesting that the reduced humoral and cellular protection in the V_N LR cohort correlated with reduced protection (Fisher's exact test, $P=0.01$). Two V_N HRs developed asymptomatic breakthrough infections during the omicron wave (Supplementary Table 2). Among the V_R subjects, 4 of the 9 V_R LRs (44.4%) developed COVID-19 (Fisher's exact test, $P=0.0006$) (Supplementary Table 2) and none of the V_R HRs (Fig. 8b). These results indicated that the reduced VOC-RBD-binding antibody titers, combined with the reduced S-specific T cell responses, correlated with the increased susceptibility of V_N LRs to break through COVID-19 caused by omicron (Supplementary Table 3).

Discussion

In the present study we show that BNT162b2 mRNA vaccine elicits broadly long-term polyreactive humoral and cellular immunity against S derived from the most widespread VOCs, including omicron. Based on the bimodal distribution of the S^{WT} IgG antibody titers at month 3 postvaccination, we subdivided the V_N subjects into V_N HRs, who showed long-lasting and higher titers of S- and RBD-specific IgGs, similar to those observed in V_R subjects, which are characterized by robust antiviral antibody responses^{16–18}, and V_N LRs who showed reduced titers of RBD^O-neutralizing antibodies and decreased frequencies of S^O -specific $CD8^+$ T cells. Furthermore, V_N LRs failed to control delta and omicron infection and COVID-19.

Both the nature and the dose of antigen contribute to the phenotype and the level of heterogeneity of memory and effector T cell subsets²⁵. When we longitudinally analyzed the diversification and turnover rate of S-specific T_M cells generated after vaccination, we found predominantly $CD4^+$ and $CD8^+$ T_{CM1} cell responses to S^{WT} , S^B , S^D and S^O peptides in V_N HRs or V_R subjects, whereas T_{EM2} cell responses were prevalent in V_N LRs after vaccination. High frequencies of circulating $CD8^+$ T_{EM1} cells were also reported among multimer-epitope-specific $CD8^+$ T cells in blood up to 120 d after SARS-CoV-2 mRNA vaccination^{30,41}. Our findings suggest that V_N HRs could have a wider crossreactive memory T cell repertoire, which can recirculate in tissues and be potentially more responsive after antigen re-encounter. Although T cell responses induced by vaccination or infection can crossrecognize S protein, as also reported by others^{42–44}, the frequency of IFN- γ -producing $CD4^+$ T cells and $CD8^+$ T cells were significantly lower in V_N LRs compared with the response to S^{WT} . Decreased responses against S^O have been also reported in subjects convalescent from SARS-CoV-2⁴⁴.

We used multiparametric flow cytometry to evaluate the phenotype of antigen-specific T cells following S-derived peptide stimulation in vitro. In line with previous studies^{30,45}, the possibility of using overlapping peptide pools, targeting multiple regions in the S protein, offers the unique opportunity to evaluate the overall T cell responses against several epitopes, thus overcoming the limitation of peptide recognition by often unknown polymorphic human leukocyte antigen (HLA) molecules. In fact, peptide-multimer labeling is often restricted to donors expressing the HLA-A2 molecule.

However, our approach implies a potential caveat resulting from the possibility that peptide activation could modulate the expression of some differentiation markers expressed by S-specific T cells. The analysis of the immune phenotype of S-specific T cells at steady state will require further deeper investigations and the development of new methodological approaches.

Some similarities between V_N HRs and V_R subjects support the hypothesis of previous viral exposure⁴⁶ in V_N HRs. In these subjects, vaccination may provide a long-term, polyspecific, immunological memory. Consistent with this hypothesis, robust polyreactive memory $CD8^+$ T cells were reported in a large cohort of hepatitis C virus (HCV)-exposed individuals who did not develop hepatitis and were negative for HCV RNA and anti-HCV antibody⁴⁶. Pre-existing RNA polymerase-specific T cells have been reported in SARS-CoV-2-exposed individuals, without any evidence of infection⁴⁷.

Both humoral and cellular immunity protect from SARS-CoV-2 challenge in macaques. $CD8^+$ T cell depletion in infected macaques causes breakthrough virus infection, documented by nasal swabs, after re-challenge with SARS-CoV-2⁴⁸. In this model, viral control postvaccination with adenoviral vectors correlates with both antibody and T cell responses, and with protection against the highly mutated omicron variant¹². These findings suggest that $CD8^+$ T cells can continue to be protective at timepoints when neutralizing antibody titers decline or are below the threshold of host protection⁴⁸. Accordingly, the decreased anti-RBD-binding antibody titers associated with reduced S-specific T cell responses in V_N LR subjects could account for the reduced protection observed in this group.

We observed a higher percentage of females among V_N HRs compared with V_N LRs. Little is known about how sex may impact the immunogenicity and protection elicited by mRNA vaccine. Age- and frailty-associated decrease in humoral responses is greater in males than in females⁴⁹. The age-related decreases in antibody titers observed in males have been also associated with a decline in $CD4^+$ T cell responses⁵⁰.

In the present study, we describe three main categories of responders to mRNA vaccination on the basis of S- and RBD-specific IgG titers, S-reactive B cells and polyreactive T_M cells. Our results suggest that protection against highly mutated VOCs relied on the contribution of both humoral and cellular immunity. The distinct phenotype and frequency of $CD4^+$ and $CD8^+$ T_M cell subsets detected in V_N LRs correlated with reduced protection against COVID-19. Further investigations are needed to fully elucidate the mechanisms of differentiation of the various T cell subclasses, and how they evolve postvaccination, in parallel with the clinical outcome. In this context, analysis of the evolution of the TCR repertoire might help elucidate the distinct differentiation paths. Altogether, our observations will contribute to determine protocols to monitor long-term memory responses, and to design new vaccination and targeted booster protocols, especially for at-risk individuals.

Online content

Any methods, additional references, Nature Research reporting summaries, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41590-022-01313-z>.

Received: 18 January 2022; Accepted: 10 August 2022;

Published online: 22 September 2022

References

1. Fisher, D. & Wilder-Smith, A. The global community needs to swiftly ramp up the response to contain COVID-19. *Lancet* **395**, 1109–1110 (2020).
2. Celardo, I., Pace, L., Cifaldi, L., Gaudio, C. & Barnaba, V. The immune system view of the coronavirus SARS-CoV-2. *Biol. Direct* **15**, 30 (2020).
3. Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. *N. Engl. J. Med.* **385**, 1761–1773 (2021).

4. Moderna. Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates. Press release (2021).
5. Regev-Yochay, G. et al. Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel. *Lancet Reg. Health Eur.* **7**, 100150 (2021).
6. Baden, L.R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N. Engl. J. Med.* **384**, 403–416 (2021).
7. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N. Engl. J. Med.* **383**, 2603–2615 (2020).
8. Pegu, A. et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. *Science* **373**, 1372–1377 (2021).
9. Altmann, D. M. & Boyton, R. J. SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection. *Sci. Immunol.* **5**, eabd6160 (2020).
10. Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. *J. Virol.* **88**, 11034–11044 (2014).
11. Gallais, F. et al. Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France. *Emerg. Infect. Dis.* **27**, 113–121 (2021).
12. Chandrashekar, A. et al. Vaccine protection against the SARS-CoV-2 omicron variant in macaques. *Cell* **185**, 1549–1555.e1511 (2022).
13. Abu-Raddad, L. J. et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. *eClinicalMedicine* **35**, 100861 (2021).
14. Hall, V. J. et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet* **397**, 1459–1469 (2021).
15. Lumley, S. F. et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. *N. Engl. J. Med.* **384**, 533–540 (2021).
16. Barda, N. et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. *N. Engl. J. Med.* **385**, 1078–1090 (2021).
17. Schmidt, F. et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. *Nature* **600**, 512–516 (2021).
18. Stamatatos, L. et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science* **372**, 1413–1418 (2021).
19. Rodda, L. B. et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. *Cell* **185**, 1588–1601.e14 (2022).
20. Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639–644 (2021).
21. Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature* **595**, 426–431 (2021).
22. Anderson, E. J. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. *N. Engl. J. Med.* **383**, 2427–2438 (2020).
23. Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature* **586**, 594–599 (2020).
24. Lederer, K. et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. *Immunity* **53**, 1281–1295.e1285 (2020).
25. Pace, L. Temporal and epigenetic control of plasticity and fate decision during CD8⁺ T-cell memory differentiation. *Cold Spring Harb. Perspect. Biol.* **13**, a037754 (2021).
26. Jarjour, N. N., Masopust, D. & Jameson, S. C. T cell memory: understanding COVID-19. *Immunity* **54**, 14–18 (2021).
27. Jameson, S. C. & Masopust, D. Understanding subset diversity in T cell memory. *Immunity* **48**, 214–226 (2018).
28. Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron. *Cell* **185**, 847–859.e811 (2022).
29. Mateus, J. et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. *Science* **374**, eabj9853 (2021).
30. Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. *Science* **374**, eabm0829 (2021).
31. Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* **602**, 657–663 (2022).
32. Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature* **602**, 654–656 (2022).
33. Grifoni, A. et al. SARS-CoV-2 human T cell epitopes: aaptive immune response against COVID-19. *Cell Host Microbe* **29**, 1076–1092 (2021).
34. Romero, P. et al. Four functionally distinct populations of human effector-memory CD8⁺ T lymphocytes. *J. Immunol.* **178**, 4112–4119 (2007).
35. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* **401**, 708–712 (1999).
36. Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science* **369**, eabc8511 (2020).
37. Giles, J. R. et al. Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers. *Immunity* **55**, 557–574.e557 (2022).
38. Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature* **587**, 270–274 (2020).
39. Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell* **181**, 1489–1501.e1415 (2020).
40. Sekine, T. et al. Robust T cell immunity in convalescent Individuals with asymptomatic or mild COVID-19. *Cell* **183**, 158–168.e114 (2020).
41. Oberhardt, V. et al. Rapid and stable mobilization of CD8⁺ T cells by SARS-CoV-2 mRNA vaccine. *Nature* **597**, 268–273 (2021).
42. Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* **581**, 215–220 (2020).
43. GeurtsvanKessel, C. H. et al. Divergent SARS-CoV-2 omicron-reactive T and B cell responses in COVID-19 vaccine recipients. *Sci. Immunol.* **7**, eabo2202 (2022).
44. Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize omicron. *Nature* **603**, 488–492 (2022).
45. Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* **370**, 89–94 (2020).
46. Scognamiglio, P. et al. Presence of effector CD8⁺ T cells in hepatitis C virus-exposed healthy seronegative donors. *J. Immunol.* **162**, 6681–6689 (1999).
47. Swadling, L. et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. *Nature* **601**, 110–117 (2021).
48. McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature* **590**, 630–634 (2021).
49. Shapiro, J. R. et al. Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults. *Clin. Infect. Dis.* **75**(Suppl. 1), S61–S71 (2022).
50. Bai, J. et al. Sex, age, and ethnic background shape adaptive immune responses induced by the SARS-CoV-2 mRNA vaccine. *Front. Immunol.* **13**, 786586 (2022).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2022

Methods

Cohort. In total, 379 staff members of CCI were recruited for the study (Supplementary Table 1). CCI is a certified COVID-free oncological hospital. All the employers have been constantly tested for SARS-CoV-2 infection by PCR following a stringent schedule. Starting from February 2020 to date, each individual has been screened: every 2–4 weeks (subjects were chosen randomly during this timeframe to ensure a daily check in each branch of the hospital); after 5 days out of office; and after close contact with a SARS-CoV-2-infected subject. In case of close contact with an infected subject, participants were isolated in quarantine for 14 days; during this timeframe, they were PCR tested each week until December 2021 or PCR screened every day for 2 weeks (from January 2022). All participants were tested for N^{WT} and S^{WT} IgG levels in plasma at T0.

Participants classified as V_N were classified into V_NLRs , V_NHRs and nonresponders (NRs). NRs were characterized by S^{WT} IgG values <50 a.u. ml^{-1} at 6 weeks after vaccination and the remaining naive subjects' IgG values were used to define a threshold to discriminate between V_NLRs and V_NHRs , leveraging 3 months of IgG data. The distribution of 3-month IgG values for multimodality was tested ($P < 2.2 \times 10^{-16}$, excess mass test) and the antimode (135 a.u. ml^{-1}) was located with the expectation of a bimodal data distribution. This antimode value was used to discriminate between V_NLRs and V_NHRs (<135 a.u. ml^{-1} and >135 a.u. ml^{-1} at 3 months, respectively). In addition, subjects with IgG titers >5 a.u. ml^{-1} at T0 were defined as seropositive.

Subjects with a documented SARS-CoV-2 infection who recovered from COVID-19 with mild symptoms (subjects with post-acute COVID-19 syndrome, long COVID or lingering symptoms were not included in the study) were classified into V_RLRs and V_RHRs with the same methodology applied for naive subjects: 3-month IgG values were tested for multimodality ($P = 0.49$, excess mass test) and split using the antimode 112 a.u. ml^{-1} located with the expectation of a bimodal data distribution. For the analysis shown in Figs. 2–7, subjects in each class were ranked according to three criteria: (1) subjects were split into three age categories (reported in order of priority for analysis): from 40 years old (y.o.) to 50 y.o., <40 y.o. and >50 y.o.; (2) in these age categories, subjects were ranked by age (from youngest to oldest); and (3) in these age categories, subjects were ranked by measured IgG values at 3 months (from highest to lowest). In addition the gender was also taken into consideration. The top ranking subjects from each class were selected for analysis. According to the S^{WT} IgG quantification and the ranking mentioned above, we decided to focus our analysis on 123 subjects who received the BNT162b2 vaccination (Supplementary Table 2). These subjects were divided into three groups: 43 V_NLRs , 42 V_NHRs and 38 V_R donors. Blood samples were collected before the first BNT162b2 mRNA (Comirnaty, Pfizer Biontech) vaccine dose (T0), before the second vaccine dose (week 3) and after 6 weeks, 3 and 6 months from the first immunization. Blood samples were also collected 1 month after the third vaccine dose (10 months after T0). 96% of donors received BNT162b2 mRNA vaccine as third dose, whereas the remaining 4% received mRNA-1273 Moderna vaccine. Data shown in Fig. 2 to 7 and in Extended Data Fig. 2 to 9 were obtained from donors immunised with BNT162b2 mRNA vaccine. All donors signed informed consent forms approved by the Ethical Committee of the CCI; participants did not receive compensation.

Sample processing. Blood samples were collected into heparin tubes via phlebotomy. Tubes were centrifuged at $800g$ for 5 min and $4^\circ C$ to separate plasma that was used for serological analysis. Whole blood was diluted 1:1 with phosphate-buffered saline (PBS) 1 $\times$ (Sigma-Aldrich) and PBMC isolation was obtained by density gradient centrifugation using Lympholyte (Cederlane). Tubes were centrifuged at $805g$ for 30 min at room temperature and PBMCs were collected into new tubes. Cells were washed with PBS 1 $\times$, centrifuged at $515g$ for 10 min and $4^\circ C$, counted with the Burkert chamber and cryopreserved in 10% dimethyl sulfoxide in fetal bovine serum (FBS; BioWest).

Spike IgM and IgG quantification. Chemiluminescence immunoassay was performed with TGS COVID-19 Control Set (Technogenetics CVCLCSGM), TGS COVID-19 IgM (CVCL100M) and TGS COVID-19 IgG (CVCL100G) according to the manufacturers' instructions to quantify IgM and IgG.

Recombinant N^{WT} , S^{WT} , S^P , S^O and S^B -RBD antigen expression and purification. Recombinant SARS-CoV-2 N- and S-RBDs were produced using poly(ethyleneimine)-based transient transfection of Freestyle HEK293 Cells (HEK293-F, Life Technologies) cultivated in suspension. Briefly, cell medium containing the secreted proteins of interest was collected 6 d after transfection by centrifugation at $1,000g$ for 15 min. The samples were loaded on to a 5-ml His-Trap excel column (Cytiva) using a peristaltic pump and then eluted with 3–250 mM imidazole gradient using an NGC fast protein liquid chromatography system (BioRad). Peak fractions containing the antigens of interest were subjected to immediate concentration with concomitant buffer exchange with fresh PBS to remove imidazole using Amicon centrifugal filters (Merck). Quality controls during protein purification were carried out using reducing and nonreducing sodium dodecylsulfate–polyacrylamide gel electrophoresis analysis and differential scanning fluorimetry with a Tycho NT.6 instrument (Nanotemper). All samples

were concentrated to 1 mg ml^{-1} , flash-frozen in liquid nitrogen and kept at $-80^\circ C$ until usage.

ELISA. SARS-CoV-2 N and SARS-CoV-2 S-RBD-specific-binding IgG antibodies were longitudinally tested by ELISA. Maxisorp ELISA 96-well plates (Thermo Fisher Scientific) were coated with $1 \mu g$ ml^{-1} of SARS-CoV-2 nucleocapsid or $2 \mu g$ ml^{-1} of S-RBD WT , -RBD P or -RBD O protein in 1 $\times$ DPBS and incubated at $4^\circ C$ overnight. After incubation, plates were washed 3 $\times$ with PBS containing 0.1% Tween-20 (PBS-T) and blocked with PBS-T supplemented with 3% bovine serum albumin (BSA; Sigma-Aldrich) for 1 h at room temperature. After washing, plasma was added and incubated for 1.5 h at room temperature. Plasma was diluted in 1% BSA in PBS-T starting from 1:25 or 1:100 dilution and serially diluting each sample by 1:4. Plates were washed 3 $\times$ with PBS-T and then the secondary antibody (anti-human IgG peroxidase, BD), in 1% BSA and PBS-T, was added and the plates were incubated for 1 h at room temperature. After three washes with PBS-T, plates were developed with TMB Substrate Kit (Thermo Fisher Scientific) at room temperature. The reaction was stopped with 1 M chloridric acid and the plates were read on a Tecan Spark plate reader at 450 nm. Optical densities (ODs) were background subtracted. A positive control standard was created by pooling plasma from six V_R subjects, whereas a negative control standard was created by pooling plasma from six pre-pandemic processed plasma samples. Positive and negative control standards were run on each plate. The limit of detection (LOD) was defined as 1:25 for IgG or otherwise stated. The limit of sensitivity (LOS) was established on the basis of uninfected subjects, using plasma from donors never exposed to SARS-CoV-2. For each sample, the ELISA endpoint titer was calculated using nonlinear regression interpolation curve fitting based on the positive control standard. Titers were calculated as the reciprocal serum dilution that yields a corrected OD value of 0.1. Similar results were achieved using Sino Biological SARS-CoV-2 S-RBD proteins.

HEK293TN-hACE2 cell-line generation. HEK293TN-hACE2 (human angiotensin-converting enzyme 2) cell line was generated by lentiviral transduction of HEK293TN cells. HEK293TN cells were obtained from System Bioscience. Lentiviral vectors were produced following a standard procedure based on calcium phosphate co-transfection with third-generation helper and transfer plasmids. The following helper vectors were used (gifts from D. Trono): pMD2.G/VSV-G (Addgene, catalog no. 12259), pRSV-Rev (Addgene, catalog no. 12253) and pMDLg/pRRE (Addgene, catalog no. 12251). The transfer vector pLenti_hACE2_HygroR was obtained by cloning of hACE2 from pcDNA3.1-hACE2 (a gift from F. Li, Addgene, catalog no. 145033) into pLenti-CMV-GFP-Hygro (a gift from E. Campeau and P. Kaufman, Addgene, catalog no. 17446). The hACE2 cDNA was amplified by PCR and inserted under the cytomegalovirus promoter of the pLenti-CMV-GFP-Hygro after green fluorescent protein (GFP) excision with XbaI and SalI digestion; pLenti_hACE2_HygroR is now available through Addgene (catalog no. 155296). After transduction with hACE2 lentiviral vector, cells were subjected to antibiotic selection with hygromycin at $250 \mu g$ ml^{-1} . Expression of hACE2 cells was confirmed by flow cytometry staining using anti-hACE2 primary antibody (AF933, R&D Systems) and rabbit anti-goat IgG secondary antibody (Alexa Fluor-647). HEK293TN-hACE2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FBS, 1% glutamine, 1% penicillin–streptomycin and $250 \mu g$ ml^{-1} of hygromycin (Gibco) and expression of hACE2 was found to be stable after multiple passages.

Plasmids and molecular cloning. The pCAGGS plasmid containing the sequence encoding for carboxy-terminal, His-tagged Wuhan SARS-CoV-2 Spike RBD (catalog no. NR_52310) was obtained from BEI Resources. Variants were generated by replacing the SARS-CoV-2 Wuhan RBD-encoding sequence with synthetic sequences (Genewiz), encoding for either SARS-CoV-2 RBD delta or SARS-CoV-2 RBD omicron variants into the pCAGGS plasmid template using the 5'-XbaI and 3'-NotI restriction sites.

Production of SARS-CoV-2 pseudoparticles. To generate lentiviral particles pseudotyped with SARS-CoV-2 S, we constructed a series of expression plasmids each encoding a SARS-CoV-2 S mutant. Briefly, for each variant, the corresponding C-terminal-deleted (19 amino acids) S complementary DNA was cloned in pcDNA3.1. Then, pLenti CMV-GFP-TAV2A-LUC Hygro was generated from pLenti-CMV-GFP-Hygro (Addgene, catalog no. 17446) by addition of T2A-Luciferase through PCR cloning. To produce the pseudotyped lentiviral particles, 5×10^6 HEK293TN cells were plated in a 15-cm dish in complete DMEM medium and co-transfected on the following day with $32 \mu g$ of plasmid pLenti CMV-GFP-TAV2A-LUC Hygro, 12.5 mg of pMDLg/pRRE (Addgene, catalog no. 12251), 6.25 mg of pRSV-Rev (Addgene, catalog no. 12253) and $9 \mu g$ of S plasmid. The medium was replaced with complete Iscove's modification of DMEM 12 h before transfection. Some 30 h after transfection, the supernatant was collected, clarified by filtration through 0.45 - μm pore-size membranes and concentrated by ultracentrifugation (SW32Ti rotor). Viral pseudoparticle suspensions were aliquoted and stored at $-80^\circ C$.

Neutralization assay. For the neutralization assay with pseudotyped particles, HEK293TN-hACE2 cells were plated 10,000 per well in white 96-well plates in complete DMEM. After 24 h, cells were transduced with 0.1 multiplicity of infection of SARS-CoV-2 pseudovirus previously incubated with a serial threefold dilution of inactivated plasma to obtain a 7-point dose-response curve. Then, 5 µl of each dilution was added to 45 µl of DMEM containing the pseudovirus and incubated for 1 h at 37 °C. The serum/pseudovirus mixture, 50 µl, was then added to each well and the plates were incubated for 24 h at 37 °C. Each point was assayed in triplicate. After 24 h of incubation, cell transduction was measured by luciferase assay using Bright-Glo Luciferase System (Promega) and Infinite F200 plate reader (Tecan). Measured relative light units were normalized with respect to controls and dose-response curves were generated and neutralization dose 50 (ND₅₀) calculated by nonlinear regression curve fitting with GraphPad Prism.

In vitro stimulation. Frozen PBMCs were thawed in complete medium (RPMI supplemented with 2.5% human serum from Aurogene, 1% L-glutamine, 1% penicillin-streptomycin, 1% nonessential amino acids, 1% sodium pyruvate and 0.1% 2-mercaptoethanol). PBMCs were centrifuged at 515g for 10 min and 4 °C, counted with the Burk chamber and resuspended in complete medium. PBMCs were cultured for either 14 h or 24 h with peptide megapools, prepared as previously described²⁸, consisting in overlapping 15-mers by 10 amino acids covering the complete sequence of the S protein of the WT SARS-CoV-2 (GenBank, accession no. MN_908947) as well as beta, delta and omicron SARS-CoV-2 variants (1 µg ml⁻¹). Complete medium was used as a negative control. Dynabeads human T-activator CD3/CD28 (from Gibco, 1:1 bead:cell ratio) supplemented with human (h)IL-2 (from Novartis, 40 U ml⁻¹) was included as a positive control. To analyze the effector and cytotoxic functions, after 14 h of incubation, PBMCs were stimulated with phorbol 12-myristate 13-acetate (Sigma-Aldrich, 20 ng ml⁻¹) and ionomycin (Sigma-Aldrich, 1 µg ml⁻¹). After 1 h, Brefeldin A (Sigma-Aldrich, 5 µg ml⁻¹) was added and the combined treatment lasted 4 h more. For each condition, triplicate wells containing 3 × 10⁵ cells in 200 µl were plated in 96-well round-bottomed plates and incubated at 37 °C with 5% CO₂. The same subjects have been analyzed longitudinally.

Intra-/extracellular staining and flow cytometry analysis. After 14 h of incubation, PBMCs were stained for intracellular cytokines combined with surface markers, whereas after 24 h PBMCs were stained for only surface markers. Cells were washed with 1 × PBS supplemented with 0.5% BSA and 2 mM EDTA (FACS buffer) and stained with Fixable Viability Stain 450 in 1 × PBS for 20 min at 4 °C to discriminate viable from nonviable cells. Then PBMCs were labeled with the following antibodies for multiparametric flow cytometry analysis: anti-CD3 (BD, SK7, 1:200), anti-CD4 (BD, RPA-T4, 1:400), anti-CD8 (BD, SK1, 1:600), anti-CD14 (BD, MφP9, 1:200), anti-CD16 (BD, 3G8, 1:600), anti-CD19 (BD, HIB19, 1:600), anti-CD25 (BD, 2A3, 1:200), anti-CD27 (BD, M-T271, 1:50), anti-CD45RA (BD, HI100, 1:50), anti-CD45RA (BD, 5H9, 1:200), anti-CD56 (BD, NCAM16.2, 1:200), anti-CD45RO (BD, UCHL-1, 1:200), anti-CD69 (BD, FN50, 1:50), anti-CD197 (BD, 150503, 1:100), anti-IFN-γ (BD, B27, 1:50), anti-IL-2 (BD, MQ1-17H12, 1:100), anti-Granzyme B (BD, GB11, 1:100) and anti-TNF-α (BD, MAB11, 1:100). Dilutions are indicative, because each antibody batch has been titrated. Surface staining was performed in FACS buffer for 30 min at 4 °C. Then, cells were washed and fixed with 1% paraformaldehyde in 1 × PBS. For the intracellular cytokines staining, after fixation, cells were permeabilized with 1 × Perm/Wash buffer (BD) according to the manufacturer's instructions and stained for 1 h at room temperature in BD Perm/Wash buffer. Cells were then washed twice and resuspended in FACS buffer for data acquisition. The same subjects have been analyzed longitudinally. Flow cytometry data were acquired on a BD LSR Fortessa X-20 instrument and analyzed with FlowJo software. The LOD for antigen-specific CD4⁺ and CD8⁺ T cell responses was calculated as the geometric twofold s.d. from the negative control (unstimulated). The LOS for antigen-specific CD4⁺ and CD8⁺ T cell responses was calculated as the median twofold s.d. from the negative control (unstimulated)²⁸. When LOD and LOS were negative or 0, we considered as active responses only those >0.01 after background subtraction. No detected responses are labeled ND.

Detection of SARS-CoV-2 antigen-specific B cells. The analysis of SARS-CoV-2 antigen-specific B cells was performed using the SARS-CoV-2 B Cell Analysis Kit (Miltenyi) according to the manufacturer's instructions. PBMCs were labeled with two tetramers formed from a recombinant SARS-CoV-2 S^{WT} protein (conjugated with phycoerythrin (PE) and PE-Vio), combined with the following antibodies: anti-CD19, anti-CD27, anti-IgG, anti-IgA and anti-IgM.

Analysis of VOC prevalence. Aggregated GISAID (<https://doi.org/10.1002/gch2.1018>) and aggregated COVID-19 case data for the percentage distribution of VOCs in Italy was downloaded from the European Centre for Disease Prevention and Control (<https://www.ecdc.europa.eu/en/publications-data/data-virus-variants-covid-19-eueea>; access date 15 April 2022).

Statistical analysis. Wilcoxon's signed-rank (nonparametric, paired), Wilcoxon's rank-sum (nonparametric, unpaired) and Spearman's correlation tests were used for statistical analysis and the *P* value was determined using Prism software (Graphpad Software, Inc.), or otherwise as indicated in the text. Significance of ratio was assessed by Wilcoxon's signed-rank *t*-test compared with a hypothetical median of 1. **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Acknowledgements

We thank M. Olivero, L. Palmas, R. Albano and D. Baev for helpful discussion and technical support, the CCI and AVIS volunteers for donating their blood and the nurses for their assistance. We thank all the IIGM and CCI colleagues for helpful discussions and all technicians for help. We thank A. Pinnola for support with molecular cloning and A. Canciani for support with antigen purification. L.P. received funding from IIGM/CSP, Armenise-Harvard Foundation, Ministero della Salute 'COVID-2020-12371849', FPO/Candiolo Advance 5 × 1000_2018 'Im-MEMORY'; A. Sapino received funding from FPFC 5 × 1,000 M.I.U.R 2017 'INTERONC-EMALAB'; FPO 5 × 1000 Ministero Salute 2018 'EMALAB'; Ministero Salute Ricerca Corrente 2021. F.F. received funding from Armenise-Harvard Foundation, AIRC 'MFAG 20075', NATO 'SPS G5701', Velux Stiftung '1375', Mizutani Foundation for Glycoscience '200039' and MUR (Dipartimenti di Eccellenza 2018–2022); and obtained funding through BEI Resources, the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH): vector pCAGGS containing the SARS-related coronavirus 2, Wuhan-Hu-1 spike glycoprotein receptor-binding domain (RBD) (no. NR-52309). A. Sette received funding from federal funds from the NIAID, NIH and Department of Health and Human Services under contract no. 75N93021C00016, and V.B. from AIRC (no. IG-2017 ID 19939).

Author contributions

L.P., A. Sottile, A. Sapino and V.B. conceived the project. L.P., A. Sottile, A. Sapino, V.B., I.E., N.B., G.M., S.A.S., V.R., C.D.I., K.G., D.B., F.F. A.G., A.S., S.M., R.D., S.M. and F.F. performed the methodology. I.E., N.B., G.M., S.A.S., V.R., C.D.I., K.G., D.B., F.F., M. Macagno, M. Montone and B.M. carried out the investigations. L.P., A. Sottile, A. Sapino, V.B., I.E., N.B., G.M., S.A.S., V.R. and C.D.I. visualized the study. L.P., A. Sottile, A. Sapino and V.B. acquired the funding. L.P., A. Sottile and A. Sapino administered the project. L.P., A. Sottile and A. Sapino supervised the project. L.P., V.B., A. Sapino, I.E., S.A.S., V.R. and C.D.I. wrote the manuscript.

Competing interests

A. Sette is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. All other authors declare no conflicts of interest. L.J.I. has filed for patent protection for various aspects of T cell epitope and vaccine design work. CCI has filed a patent for immune correlate of protection after RNA vaccination. R.D.F. is a consultant for Moderna Inc. The data are tabulated in the main paper and in the supplementary materials.

Additional information


Extended data Extended data are available for this paper at <https://doi.org/10.1038/s41590-022-01313-z>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41590-022-01313-z>.


Correspondence and requests for materials should be addressed to Luigia Pace.

Peer review information *Nature Immunology* thanks Tao Dong, Mala Maini and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Ioana Visan, in collaboration with the *Nature Immunology* team.

Reprints and permissions information is available at www.nature.com/reprints.




Extended Data Fig. 1 | Longitudinal analysis of humoral responses to BNT162b2 mRNA vaccine. **a**, ELISA showing N^{WT} antibody titers of SARS-CoV-2 naïve (n = 331) and SARS-CoV-2 recovered V (n = 48) subjects measured at T0. All data are shown as ELISA ETs based on a standard. The dotted line indicates LOD. **b**, CLIA analysis showing S^{WT} IgM titers in naïve, seropositive and recovered subjects at T0, weeks 3 and 6 and months 3 and 6. NR subjects are also reported. **c**, CLIA analysis showing S^{WT} IgG titers in V_R subjects divided in V_RLRs and V_RHRs at T0, weeks 3 and 6 and months 3 and 6. **d**, CLIA analysis showing S^{WT} IgG titers in V_N (LRs and HRs) and V_R (V_RLRs and V_RHRs) subjects at month 6 vs subjects' age. **e**, CLIA analysis showing S^{WT} IgG titers in V_N (V_NLR and V_NHR) and V_R (V_RLR and V_RHR) subjects at month 6 grouped by age range. The same subjects were longitudinally analyzed. Boxes show median, upper and lower quartiles, and whiskers show 1.5x the interquartile range (IQR) on either side (panels b,c,e) or minimum/maximum (panel a). Each dot represents one subject. Each dot of box plots represents the average between two technical replicates of the same subject. All data are pooled. Statistics were calculated using two-sided Wilcoxon rank-sum test (panels a,c,e) or signed-rank test (panel b), with Benjamini Hochberg correction for multiple testing. **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.




Extended Data Fig. 2 | See next page for caption.

Extended Data Fig. 2 | Analysis of B cell responses to SARS-CoV-2 BNT162b2 mRNA vaccine. **a**, Gating strategy ancestry: lymphocytes (FSC-A/SSC-A), FSC singlets (FSC-W/FSC-A), SSC singlets (SSC-W/SSC-A), live cells (PerCp-Cy5.5-7-AAD/FSC-A), CD19⁺ cells (APC-Cy7-CD19/FSC-A), S^{WT} cells (PE-Vio-S^{WT} tetramer/PE-S^{WT} tetramer). IgM vs CD27 (APC-IgM/FITC-CD27), IgG vs CD27 (BV421-IgG/FITC-CD27), IgA vs CD27 (BV510-IgA/FITC-CD27) on gated CD19⁺ cells (positive control) and on gated S^{WT}+ CD19⁺ B cells. **b**, Flow cytometry analysis showing the percentage of CD19⁺ B cells in V_NLR, V_NHR and V_R subjects at month 6. **c**, Representative flow cytometry dot plots of S^{WT}-specific tetramer⁺ CD19⁺B cells from V_NLR, V_NHR and V_R subjects at T0. **d**, Flow cytometry analysis showing the percentage of CD27⁺ IgM⁺ S^{WT}- tetramer⁺ B cells in V_NLR, V_NHR and V_R subjects at T0, week 6 and month 6. Below: percentages of V_NLR, V_NHR and V_R subjects with active responses > 0.01. **e**, Flow cytometry analysis showing the cell number of CD27⁺ IgA⁺ S^{WT}- tetramer⁺ B cells per 10⁶ PBMCs in V_NLR, V_NHR and V_R subjects at T0, week 6 and month 6. At T0: V_NLR (n = 25), V_NHR (n = 24), V_R subjects (n = 12). At week 6: V_NLR (n = 12), V_NHR (n = 17), V_R subjects (n = 10). At month 6: V_NLR (n = 26), V_NHR (n = 29), V_R subjects (n = 22). The same subjects were longitudinally analyzed. Box plots indicate median, interquartile range and minimum/maximum. Each dot of box plots represents the average between three technical replicates of the same subject. All data are pooled from multiple experiments. The dashed black line indicates LOD. Statistics were calculated using two-sided Wilcoxon rank-sum tests. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.




Extended Data Fig. 3 | Analysis of anti S-RBD^{WT} -RBD^D and -RBD^O binding Abs. a. ELISA titration analysis showing S-RBD^{WT}, -RBD^D and -RBD^O IgG from representative V_{NLR} s ($n=3$), V_{NHR} s ($n=3$), and V_R subjects ($n=3$) at month 3. For S-RBD^{WT} IgG, plasma was diluted starting with 1:25 dilution, followed by 1:4 serial dilutions for all subjects. For S-RBD^D and S-RBD^O IgG, plasma was diluted starting with 1:25 dilution followed by 1:4 serial dilutions for V_{NLR} s or starting with 1:100 dilution followed by 1:4 serial dilutions for V_{NHR} s and V_R subjects.




Extended Data Fig. 4 | See next page for caption.

Extended Data Fig. 4 | Flow cytometry gating strategy. **a**, Gating strategy ancestry: lymphocytes (FSC-A/SSC-A), FSC singlets (FSC-W/FSC-A), SSC singlets (SSC-W/SSC-A), Dump⁻ live cells [Dead FVS450⁺ cells and CD14⁺ CD16⁺ CD19⁺ CD56⁺ (Dump⁺) cells excluded], CD4 vs CD8 (BV605-CD8/BV786-CD4). **b, c**, Differentiation markers on CD4⁺ (**b**) or CD8⁺ (**c**) T cells. CD4⁺ or CD8⁺ T cells, CD25 vs CD69 (BV-510-CD25/APC-R700-CD69). CD4⁺ or CD8⁺ T cells with high gMFI levels for both CD25 and CD69 were gated as double positive cells. CD45RA (APC-CD45RA/FSC-A) on gated CD4⁺ or CD8⁺ and on gated CD25⁺ CD69⁺ CD4⁺ or CD8⁺ T cells, CCR7 vs CD27 (BV711-CCR7/ APC-H7-CD27) on gated CD45RA⁻ and on gated CD45RA⁺ cells. **d, e**, Flow cytometry analysis showing the percentage of CD4⁺ (**d**) and CD8⁺ (**e**) T cells in V_NLRs (n=25), V_NHRs (n=24), and V_R subjects (n=12) at month 6. **f, g**, Representative flow cytometry dot plots of CD25 vs CD69 cells on gated CD4⁺ (**f**) and CD8⁺ (**g**) T cells from V_NLRs, V_NHRs and V_R subjects at T0, after 24h incubation with Medium (Unstimulated) or S^{WT}. Data are represented with background subtraction from paired unstimulated controls. The same subjects were longitudinally analyzed. Box plots indicate median, interquartile range, and minimum/maximum. Each dot of box plots represents the average between three technical replicates of the same subject. All data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon rank-sum tests.




Extended Data Fig. 5 | Analysis of specific CD4⁺ and CD8⁺ T cell responses against S^{WT}, S^D, S^O and S^B in V_{NLR}, V_{NHR} and V_R subjects. **a, b, Flow cytometry analysis showing the percentage of CD25⁺CD69⁺CD4⁺ (**a**) and CD25⁺CD69⁺CD8⁺ (**b**) T cells in V_{NLR}s (n=25), V_{NHR}s (n=24), and V_R subjects (n=12) at T0 and month 6, after 24h incubation with S^{WT}, S^D, S^O or S^B peptide megapools. **c, d**, Flow cytometry analysis showing the percentage of CD25⁺CD69⁺CD4⁺ (**c**) and CD25⁺CD69⁺CD8⁺ (**d**) T cells from V_{NLR}s (n=25), V_{NHR}s (n=24), and V_R subjects (n=12) at T0 and month 6, after 24h incubation with anti (α) -CD3 plus CD28 beads and IL-2. Data are represented with background subtraction from paired unstimulated controls. The same subjects were longitudinally analyzed. Each dot of box plots represents the average between three technical replicates of the same subject. All data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon signed-rank tests. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.**




Extended Data Fig. 6 | See next page for caption.

Extended Data Fig. 6 | Analysis of effector molecules against S^{WT} , S^D , S^O and S^B in V_NLR , V_NHR and V_R subjects. **a, Gating strategy ancestry: lymphocytes (FSC-A/SSC-A), FSC singlets (FSC-W/FSC-A), SSC singlets (SSC-W/SSC-A), $CD3^+$ Dump⁻ live cells (BUV805-CD3/BV421-Dump) [Dead FVS450⁺ cells and $CD14^+$ $CD16^+$ $CD19^+$ $CD56^+$ (Dump⁺) cells excluded], CD4 vs CD8 (BV605-CD8/BV786-CD4). Intracellular effector molecules: IFN- γ (Pe-Cy7-IFN- γ /FSC-A), IL-2 (PE-IL-2/FSC-A) and TNF- α (PerCP-Cy5.5-TNF α -/FSC-A) on gated $CD4^+$ and on gated $CD8^+$ T cells. **b, c**, Flow cytometry analysis showing the percentage of IL-2⁺ (**b**) and TNF- α ⁺ (**c**) cells on gated $CD4^+$ and $CD8^+$ T cells in V_NLR s (n=25), V_NHR s (n=24), and V_R subjects (n=12) subjects at month 6, after 14h incubation with S^{WT} , S^D , S^O or S^B peptide megapools. Below: percentages of subjects with active responses > 0.01. **d**, Flow cytometry analysis showing the percentage of IFN- γ^+ , IL-2⁺ and TNF- α^+ cells on gated $CD4^+$ and $CD8^+$ T cells from V_NLR s (n=25), V_NHR s (n=24), and V_R subjects (n=12) subjects at month 6, after 14h incubation with α -CD3 plus -CD28 beads and IL-2. Data are represented with background subtraction from paired unstimulated controls. The same subjects were longitudinally analyzed. Box plots indicate median, interquartile range, and minimum/maximum. Each dot of box plots represents the average between three technical replicates of the same subject. All data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon rank-sum tests. ***P < 0.001.**




Extended Data Fig. 7 | See next page for caption.

Extended Data Fig. 7 | Analysis of specific CD4⁺ and CD8⁺ T cell responses against S^{WT}, S^D, S^O and S^B in V_NLR, V_NHR and V_R subjects. a–f. Flow cytometry analysis showing the percentage of CD25⁺ CD69⁺ CD4⁺ T_{CM1} (a), T_{EM1} (b), T_{EM2} (c) cells and CD25⁺ CD69⁺ CD8⁺ T_{CM1} (d), T_{EM1} (e), T_{EM2} (f) cells in V_NLRs (n=25), V_NHRs (n=24), and V_R subjects (n=12) at T0 and month 6, after 24h incubation with S^{WT}, S^D, S^O or S^B peptide megapools. Data are represented with background subtraction from paired unstimulated controls. The same subjects were longitudinally analyzed. Each dot of box plots represents the average between three technical replicates of the same subject. All data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon signed-rank tests. *P < 0.05; **P < 0.01; ***P < 0.001; ND = not detected.




Extended Data Fig. 8 | Polyreactive CD4⁺ and CD8⁺ T cell responses in V_{NLR}, V_{NHR} and V_R subjects. a–f, Flow cytometry analysis showing the percentage of CD25⁺CD69⁺ T_{CM1} (**a, b**), T_{EM1} (**c, d**) and T_{EM2} (**e, f**) cells on gated CD4⁺ (**a, c, e**) and CD8⁺ (**b, d, f**) T cells from V_{NLR}s (n=25), V_{NHR}s (n=24), and V_R subjects (n=12) at T0 and month 6, after 24h incubation with α-CD3 plus -CD28 beads and IL-2. The dotted black lines indicate the LOD. The dotted green lines indicate the LOS. The same subjects were longitudinally analyzed. Data are represented with background subtraction from paired unstimulated controls. Box plots indicate median, interquartile range, and minimum/maximum. Each dot of box plots represents the average between three technical replicates of the same subject. All data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon rank-sum tests.



Extended Data Fig. 9 | See next page for caption.

Extended Data Fig. 9 | Analysis of S-specific T_N , T_{CM2} , and T_{EMRA} cell responses on gated $CD25^+ CD69^+ CD4^+$ and $CD8^+$ T cells. a-f, Flow cytometry analysis showing the percentage of T_N (**a, d**), T_{CM2} (**b, e**) and T_{EMRA} (**c, f**) cells on gated $CD25^+ CD69^+ CD4^+$ (**a-c**) and $CD8^+$ (**d-f**) T cells from V_N LRs ($n=25$), V_N HRs ($n=24$), and V_R subjects ($n=12$) at T0 and month 6, after 24h incubation with S^{WT}, S^D , S^O or S^B peptide megapools. The dotted black lines indicate the LOD. The dotted green lines indicate the LOS. Below: percentages of subjects with active responses > 0.01 . Data are represented with background subtraction from paired unstimulated controls. The same subjects were longitudinally analyzed. Box plots indicate median, interquartile range, and minimum/maximum. Each dot of box plots represents the average between three technical replicates of the same subject. All data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon rank-sum tests. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.



Extended Data Fig. 10 | Analysis of specific CD4⁺ and CD8⁺ T cell responses against S^{WT} , S^D , S^O and S^B in V_{NLR} , V_{NHR} and V_R subjects, at months 6 and 10 postvaccination. **a, b, Flow cytometry analysis showing the percentage of $CD25^{+} CD69^{+} CD4^{+}$ (**a**) and $CD8^{+}$ (**b**) T cells in V_{NLR} s ($n=13$), and V_{NHR} s ($n=12$) at months 6 and 10, after 24h incubation with S^{WT} , S^D , S^O or S^B peptide megapools. The same subjects were longitudinally analyzed. Data are represented with background subtraction from paired unstimulated controls. Each dot of box plots represents the average between three technical replicates of the same subject. All data are pooled from multiple experiments. Statistics were calculated using two-sided Wilcoxon signed-rank tests. * $P < 0.05$.**

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- ☐ ☒ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- ☐ ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- ☐ ☒ The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- ☒ ☐ A description of all covariates tested
- ☐ ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- ☐ ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- ☐ ☒ For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- ☒ ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- ☒ ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- ☐ ☒ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The first aim of the study was to characterize the anti-spike antibody levels after mRNA vaccination against SARS-CoV-2 in a wide cohort of subjects. Giving the exploratory design of the study, the characteristics of the participants were not pre-established. A number of selected individuals, representative of the whole cohort, was deeply investigated for further flowcytometric analysis. All informations are included in the manuscripts.
Data exclusions	No data points were excluded.
Replication	A cohort of 379 individuals (table S1) was analyzed for anti-spike and anti-nucleocapsid antibody responses before and after vaccination (for Spike). The number of subjects analysed by flowcytometry, ELISA, and neutralization assay are listed in the manuscript, details are presented in table S2. The results obtained for each individual are shown. For anti-spike and anti-nucleocapsid antibody responses each dot represent the media average of two replicates for each subject (Fig.1). For
Randomization	No randomization was used in this study, since we are comparing three well defined cohorts: high responders, low responders and subject previously infected (EX-COVID).
Blinding	Blinding was not done in this study. The groups were defined based on the infection history and serological level of anti-spike IgG.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☐	☒ Antibodies
☐	☒ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☐	☒ Human research participants
☒	☐ Clinical data
☒	☐ Dual use research of concern

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☐	☒ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used	anti-CD3 (clone SK7), BV510, 740202, 1:200, BD OptiBuild anti-CD8 (clone SK1), BV605, 564116, 1:600, BD Horizon anti-CD14 (clone MφP9), BV421, 563743, 1:200, BD Horizon anti-CD16 (clone 3G8), BV421, 562878, 1:600, BD Horizon anti-CD19 (clone H1B19), BV421, 562440, 1:600, BD Horizon anti-CD25 (clone 2A3), BV510, 740198, 1:200, BD OptiBuild anti-CD27 (clone M-T271), APC-H7, 560222, 1:50, BD Pharmingen anti-CD45RA (clone HI100), APC, 550855, 1:50, BD Pharmingen anti-CD45RO (UCHL-1), Pe-Cy7, 560608, 1:200, BD Pharmingen anti-CD45RA (clone 5H9), FITC, 556626, 1:200, BD Pharmingen anti-CD56 (clone NCAM16.2), BV421, 562751, 1:200, BD Horizon anti-CD69 (clone FN50), APC-R700, 565154, 1:50, BD Horizon anti-CD197 (clone 150503), BV711, 566602, 1:100, BD Horizon anti-CD4 (clone RPA-T4), BV786, 740962, 1:400, BD OptiBuild anti-IFNγ (clone B27), Pe-Cy7, 557643, 1:50, BD Pharmingen anti-IL-2 (clone MQ1-17H12), PE, 560709, 1:100, BD Pharmingen anti-Granzyme B (clone GB11), AlexaFluor647, 560212, 1:100, BD Pharmingen anti-TNFα (clone MAb11), PerCP-Cy5.5, 560679, 1:100, BD Pharmingen
-----------------	--

The dilutions are indicative, as each Ab Abatch has been tested by titration.
anti-IgG HRP Peroxidase, 555788, 1:3000, BD Pharmigen

Chemiluminescence immunoassay (CLIA) was performed with TGS COVID-19 Control Set (Technogenetics CVCLCSGM), TGS COVID-19 IgM (CVCL100M) and TGS COVID-19 IgG (CVCL100G) according to the manufacturer instructions to quantify IgM and IgG.

The analysis of SARS-CoV-2 antigen-specific B cells was performed using the SARS-CoV-2 B Cell Analysis Kit (Miltenyi)

Validation

All antibodies were obtained from commercial vendors. After the evaluation of the instructions provided by the manufacturers, all antibody batches have been titrated to define the appropriate concentration for PBMC labelling, and compared with the corresponding isotype controls.

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s) Human HEK293-NT: System Bioscience LV900A-1; Human freestyle 293 (293-F): Thermofisher Scientific R79007

Authentication Short Tandem Repeat profiling

Mycoplasma contamination The cell line were tested for mycoplasma contamination and they were negative

Commonly misidentified lines (See [ICLAC](#) register) The cell lines used are not misidentified

Human research participants

Policy information about studies involving human research participants

Population characteristics The characteristics of the human research participants are described in table S1 and S2 of the manuscript.

Recruitment All the employers of Candiolo Cancer Institute were recruited.

Ethics oversight Written informed consent was obtained from all the subjects. The study was performed in accordance with the declaration of Helsinki, and approved by the FPO /CRC Candiolo istitutinal ethical board, project MemoryCoVax, N. 022-FPO21.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation PBMCs were prepared, cultured and labeled according to standard protocol.

Instrument BD Fortessa X20

Software BD FACS Diva 8.0.2, FlowJo 10.4.2

Cell population abundance N/A. No sorting was performed.

Gating strategy The B cell gating strategy starts with Lymphocyte gate based on SSC-A vs FSC-A, then singlets were identified by FSC-A vs FSC-W, followed by SSC-A vs SSC-W. Live cells were identified with 7-AAD. B cell were identified by CD19 expression. Antigen-specific WT+B cells were identified using the combination of WT-tetramers. On Total B cells and on WT+CD19+B cells IgM, IgG and IgA expression were identified in combination with CD27. (Extended Data Figure 2).
The T cell gating strategy starts with Lymphocyte gate based on SSC-A vs FSC-A, then singlets were identified by FSC-A vs FSC-W followed by SSC-A vs SSC-W. T live cells were identified with cell exclusion dyes as Live/Dead and DUMP channel composed by CD14,CD16,CD19,CD56, following T cell identification by expression of CD4 and CD8. In both CD4 and CD8 gates antigen-specific cells were identified using CD25 vs CD69 combination. On Total CD8 and CD4 and in the antigen-specific CD4+CD25+CD69+ or CD8+CD25+CD69+gate, FSC-A vs CD45RA was performed. Memory subsets were identified with CCR7 vs CD27 expression on CD45RA+ and CD45RA- on Total CD4 and CD8 T cells and CD4+CD25+CD69+ or CD8+CD25+CD69+ T cells.

(Extended Data Figure 4).

☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Supplementary information

Memory CD8⁺ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination

In the format provided by the
authors and unedited

Table S1. Characteristics of the IRCCS Candiolo cohort

	cohort	20-29	30-39	40-49	50-59	>60
Donors:	379	44 (12%)	74 (20%)	116 (31%)	95 (25%)	50 (13%)
Gender:						
female	260 (69%)	37 (14%)	42 (16%)	86 (33%)	70 (27%)	25 (10%)
male	119 (31%)	7 (6%)	32 (27%)	30 (25%)	25 (21%)	25 (21%)
Age:						
Range	23-72	23-29	30-39	40-49	50-59	60-72
Median $\pm$ IQR	47 $\pm$ 12	27 $\pm$ 3	34 $\pm$ 5	46 $\pm$ 5	54 $\pm$ 4	62 $\pm$ 4
SARS-CoV-2:						
naive	298 (79%)	30 (10%)	60 (20%)	89 (30%)	75 (25%)	44 (15%)
recovered	48 (13%)	7 (15%)	10 (21%)	16 (33%)	13 (27%)	2 (4%)
seropositive	24 (6%)	7 (29%)	2 (8%)	9 (38%)	4 (17%)	2 (8%)
non responders	9 (2%)	0 (0%)	2 (22%)	2 (22%)	3 (33%)	2 (22%)
Ethnicity:						
White	343 (91%)	40 (12%)	63 (18%)	104 (30%)	91 (27%)	45 (13%)
Black	1 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)
Hispanic	2 (1%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)	1 (50%)
Unknown	33 (9%)	4 (12%)	9 (27%)	12 (36%)	4 (12%)	4 (12%)
Vaccination schedule:						
1 st dose Pfizer	T0 (100%)					
2 nd dose Pfizer	3W (100%)					
3 rd dose Pfizer	9M (96%)					
3 rd dose Moderna	9M (4%)					

Table S2. Characteristics of the donors analyzed in figures 2-7

	V _N LR (n=43)	V _N HR (n=42)	V _R (n=38)
Age (years)			
Range	25 - 50	25 - 65	27 - 68
Median	46	48	45.5
Gender			
Male (%)	21% (9/43)	14.3% (6/42)	73.6% (29/38)
Female (%)	79% (34/43)	85.7% (36/42)	26.4% (9/38)
Race or Ethnicity			
White	100% (43/43)	100% (42/42)	97.4% (37/38)
Hispanic or Latino	0% (0/43)	0% (0/42)	2.6% (1/38)
Asian	0% (0/43)	0% (0/42)	0% (0/38)
Black	0% (0/43)	0% (0/42)	0% (0/38)
More than one	0% (0/43)	0% (0/42)	0% (0/38)
Not reported	0% (0/43)	0% (0/42)	0% (0/38)
Time between infection and vaccine	Average (Days)	-	115,26
	Median (Days)	-	60
	B cells		
	After 1st dose	After 1st dose	After 1st dose
# of donors	n=25	n=24	n=12
IgG Range	0 - 2	0 - 62.1	0 - 70.1
IgG Median ± IQR	0 ± 0	0 ± 9.1	14.65 ± 35.275
Spike IgG positive %	0% (0/12)	0% (0/12)	0% (0/12)
	After 6 weeks	After 6 weeks	After 6 weeks
# of donors	n=12	n=17	n=10
IgG Range	54.7 - 160	160 - 160	160 - 160
IgG Median ± IQR	91.75 ± 47.325	160 ± 0	160 ± 0
Spike IgG positive %	16,67% (2/12)	100% (17/17)	100% (10/10)
	After 6 months	After 6 months	After 6 months
# of donors	n=26	n=28	n= 22
IgG Range	0 - 36.9	33.4 - 160	45.6 - 160
IgG Median ± IQR	13.75 ± 10.175	88.6 ± 43.2	145.75 ± 96.15
Spike IgG positive %	0% (0/28)	14.3% (4/28)	40.9% (9/22)
	ELISA (WT, Delta, Omicron Spike-RBD)		
	After 1st dose	After 1st dose	After 1st dose
# of donors	n=30	n=30	n=26
IgG Range	0 - 2	0 - 8.7	0 - 122.8
IgG Median ± IQR	0 ± 0	0 ± 0.6	11.35 ± 55.1
Spike IgG positive %	0% (0/30)	0% (0/30)	0% (0/26)
	After 3 months	After 3 months	After 3 months
# of donors	n=28	n= 27	n= 25
IgG Range	16 - 133.8	141 - 160	44 - 160
IgG Median ± IQR	43.15 ± 24.2	160 ± 0	160± 68
Spike IgG positive %	0% (0/28)	100% (27/27)	60% (15/25)

# of donors	After 6 months n=30	After 6 months n=29	After 6 months n=26
IgG Range	0 - 80.1	47.7 - 160	13.2 - 160
IgG Median ± IQR	15.1 ± 13.825	84.6 ± 41.2	79.25 ± 122.3
Spike IgG positive %	0% (0/30)	10.3% (3/29)	50% (13/26)
# of donors	After 10 months n=24	After 10 months n=20	After 10 months n=17
IgG Range	3.7 - 160	15.3 - 160	111.5 - 160
IgG Median ± IQR	160 ± 21.175	160 ± 0	160 ± 0
Spike IgG positive %	75% (18/24)	90% (18/20)	94.1% (16/17)
	PBMCs cultures		
	After 1st dose n=25	After 1st dose n=24	After 1st dose n=12
# of donors	n=25	n=24	n=12
IgG Range	0 - 2	0 - 62.1	0 - 70.1
IgG Median ± IQR	0 ± 0	0 ± 9.1	14.65 ± 35.275
Spike IgG positive %	0% (0/25)	0% (0/24)	0% (0/12)
# of donors	After 6 months n=25	After 6 months n=24	After 6 months n=12
IgG Range	6.7 - 54.5	33.4 - 160	45.6 - 160
IgG Median ± IQR	20 ± 13.65	90.7 ± 37.6	136.45 ± 92.9
Spike IgG positive %	0% (0/25)	12.5% (3/24)	50% (6/12)
# of donors	After 10 months n=13	After 10 months n=13	After 10 months -
IgG Range	160 - 160	26.1 - 160	-
IgG Median ± IQR	160 ± 0	160 ± 0	-
Spike IgG positive %	100% (13/13)	83,3% (10/13)	-
	Neutralization test		
	After 6 months n=20	After 6 months n=20	After 6 months -
# of donors	n=20	n=20	-
IgG Range	0 - 54.5	47.7 - 160	-
IgG Median ± IQR	13.3 ± 6.975	81.8 ± 41.65	-
Spike IgG positive %	0% (0/20)	5% (1/20)	-
	V _N LR (n=236)	V _N HR (n=62)	V _R LR (n=9)
Breakthrough infection	Up to October 2021	2.1% (5/236)	0% (0/62)
	From December 2021 to April 2022	9.1% (21/231)	3.2% (2/62)
COVID-19 cases	Up to October 2021	2.1% (5/236)	0% (0/62)
	From December 2021 to April 2022	9.1% (21/231)	0% (0/62)

Samples analyzed at the different time points were longitudinally collected from the same donors

Table S3. Working model highlighting the differences among V_NLR, V_NHR and V_R subjects

	V _N LR	V _N HR	V _R
Anti-S ^{WT} and-RBD IgG	+	++	++
S ^{WT} -specific B cells	+	++	++
% CD27 ⁺ IgG ⁺ B cells	+	+	+
S ^{WT} -specific CD8 ⁺ T cells activation	CD25 ⁺ CD69 ⁺	CD25 ⁺ CD69 ⁺	CD25 ⁺ CD69 ⁺
Memory CD8 ⁺ T cells	T _{EM1} T _{EM2}	T _{CM1} T _{EM1}	T _{CM1} T _{EM2}
COVID after vaccination	V _N LR	V _N HR	V _R LR V _R HR
	+++	-	+++ -